Applied Genetic Technologies (AGTC) Reports Q2 Loss of $0.45/sh

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/27/2026

1. ORCL
2. AVGO
3. CDNS
4. ANT
5. BA
6. SPY
7. META
8. HOOD
9. INTC
10. JBLU

Go back to Applied Genetic Technologies (AGTC) Reports Q2 Loss of $0.45/sh

AGTC Announces Financial Results and Business Update for the Quarter Ended December 31, 2021

February 14, 2022 7:00 AM EST

-Company on track to provide 3-month interim SKYLINE trial results in 2Q 2022-

-Company to host management update and webcast today at 8:00 a.m. ET-

GAINESVILLE, Fla. and CAMBRIDGE, Mass., Feb. 14, 2022 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a clinical stage biotechnology company focused on the development and commercialization of adeno-associated virus (AAV)-based gene therapies for the treatment of rare and debilitating diseases with an initial focus on inherited retinal diseases (IRDs), today announced financial results for the quarter ended December 31, 2021.

... More